

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction			
Background and	2a	Scientific background and explanation of rationale	4-5
objectives	2b	Specific objectives or hypotheses	4-5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	No important
			changes
Participants	4a	Eligibility criteria for participants	5-6;
			Supplementary
			Appendix p. 2-4
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were	
		actually administered	6-7
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they	
		were assessed	7-9,
			Supplementary
			Appendix p. 5-7
	6b	Any changes to trial outcomes after the trial commenced, with reasons	No changes
Sample size	7a	How sample size was determined	Supplementary
			Appendix p. 4-5
	7b	When applicable, explanation of any interim analyses and stopping guidelines	5; 9-11
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	7;
generation			Supplementary

			Appendix p. 4
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7;
			Supplementary
			Appendix p. 4
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	7;
		describing any steps taken to conceal the sequence until interventions were assigned	Supplementary
			Appendix p. 4
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
			7;
			Supplementary
			Appendix p. 4
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	
		assessing outcomes) and how	Supplementary
			Appendix p. 4
	11b	If relevant, description of the similarity of interventions	6-7;
			Supplementary
			Appendix p. 4
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9-11;
			Supplementary
			Appendix p. 5-7
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	9-11;
			Supplementary
			Appendix p. 5-7
Results			
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	
diagram is strongly		were analysed for the primary outcome	11; Fig. 1 p. 26;
recommended)			Figure S1
,			Supplementary
			Appendix p. 11;
			Figure S2
			Supplementary
			Appendix p. 12-
			13

	13b	For each group, losses and exclusions after randomisation, together with reasons	Fig. 1 p. 26; Fig.
	.00	r er each greap, recess and exercising and randomisation, regenier man reasons	S2
			Supplementary
			Appendix p. 12-
			13
Recruitment	14a	Dates defining the periods of recruitment and follow-up	11
	14b	Why the trial ended or was stopped	Study ongoing
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1 p. 29
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis	
		was by original assigned groups	Table 2 p. 30
Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	
estimation		precision (such as 95% confidence interval)	Table 2 p. 30
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table 2 p. 30
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
		pre-specified from exploratory	12-14; 16-17
			Supplementary
			appendix: Fig
			S6 p.17; Fig S7
			p. 18; Fig S9 p.
			20 p. 20; Table
			S3, p 25; Table
			S9, p. 32; Table
Hamas	40	All insurant out because an unintereded offerto in each arrays of	S10, p. 33
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	14-15; Fig 2 p.
			27;
			Supplementary appendix: Tabel
			S6 p. 28-29:
			Table S7 p. 30
			1 able 31 p. 30
Discussion Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20-21
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	18-21
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	18-21

Other information			
Registration	23	Registration number and name of trial registry	
			_ 5
Protocol	24	Where the full trial protocol can be accessed, if available	Provided as
			supplementary
			material
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	23

^{*}We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.